Organization · Venture Capital
Bioasia Investments
Bioasia Investments, now known as Vivo Capital, is a global healthcare investment firm focused on life sciences, including biotechnology and pharmaceuticals. It operates across multiple investment stages and geographies.
Overview
What Bioasia Investments does
What Bioasia Investments is
Bioasia Investments, now known as Vivo Capital, is a global healthcare investment firm focused on life sciences, including biotechnology and pharmaceuticals. It operates across multiple investment stages and geographies.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 1996
- Approximate age
- About 30 years
- Structured capabilities
- Funder
- Last reviewed
- April 26, 2026
Official channels
Find Bioasia Investments elsewhere
Open the official website or a supported primary organization account.
Capability profile
Bioasia Investments as a funder
Investment thesis
Bioasia Investments, now known as Vivo Capital, focuses on healthcare specialization and an ecosystem strategy, investing globally to create value through a network of portfolio companies and industry partners.
Focus narrative
Vivo Capital specializes in the life sciences sector, targeting investments in biotechnology, pharmaceuticals, and medical devices. The firm is dedicated to supporting innovative healthcare companies that demonstrate scientific, clinical, regulatory, or commercial potential, leveraging its extensive network to foster international partnerships and collaborations.
Value beyond capital
Vivo Capital adds value to its portfolio companies through its extensive network of industry partners, operating executives, and advisors, facilitating international partnerships and cross-value-chain collaborations. The firm’s expertise in healthcare investment allows it to provide strategic guidance and support to enhance the growth and success of its portfolio companies.
Focus and fit
- Stages
- Friends and Family · Angel · Accelerator · Pre-seed · Seed · Seed+ · Series A · Series A+ · Series B · Series B+ · Series C · Series C+ · Series D · Series E · Series F · Growth Equity · Pre-IPO · Ipo
- Sectors
- Biotech · Healthcare · Medical Devices · Diagnostics
- Regions
- Global · North America · Greater China · Asia
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 430
- Recorded notable exits
- Terns Pharmaceuticals, Scientia Vascular, and 35Pharma
Portfolio context
Notable portfolio companies include Kinaset Therapeutics, which recently raised $100M in a Series B round, and EpiBiologics, which secured $107M in funding. Vivo Capital has also been involved in significant exits, such as the acquisition of Terns Pharmaceuticals for $6.7B and Scientia Vascular for $550M.
Common questions
What to know about Bioasia Investments
Upseed classifies Bioasia Investments under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 26, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.